Biopharma Deal Value, Volume Tumbled Substantially During First Half

04 Aug 2020

A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.

Straight_Road — After a decline in deal-making during the first half, PwC expects higher activity during latter 2020

The biopharmaceutical industry has fared better than many others during the COVID-19 pandemic, but it hasn’t escaped disruption. A new PwC analysis shows that deal-making decreased precipitously during the first six months of 2020, both by aggregate value and volume.

In a survey of deals valued at $15m or higher, PwC analysts found just $3.3bn in total big pharma deal value during the second quarter of 2020, even though the total number of deals rose from 19 during the first quarter to 22 during the second

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

06 May 2025

• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

05 May 2025

• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

In Brief: Sanofi Gains €10bn From Opella Sale

02 May 2025

• By Sushmita Panda

Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

01 May 2025

• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.